Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05670782 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease
A Phase 2 study of Parkinson Disease, sponsored by FAScinate Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
- 3
- Study locations
NCT05670782: Active Phase 2 study of Parkinson Disease, sponsored by FAScinate Therapeutics.
NCT05670782 is a Phase 2 study of Parkinson Disease that is active but no longer recruiting, run by FAScinate Therapeutics. The registered enrollment target is 314 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05670782, a Phase 2 study of Parkinson Disease, is active but no longer recruiting, sponsored by FAScinate Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KM-819
Study Locations (3)
California
- Parexel Early Phase Clinical Unit - Glendale
- University California San Diego Medical Center - San Diego
Michigan
- Quest Research Institute, Rose Cancer Center - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2025-11-13 |
| Phase | Phase 2 |
What the registry record for NCT05670782 still lists
NCT05670782 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05670782 reports a single indexed study location in California, Michigan.
Frequently Asked Questions
What is clinical trial NCT05670782 about?
NCT05670782 is a clinical study titled "A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease". The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.
What is the current status of trial NCT05670782?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2022-07-19. Estimated completion is 2025-11-13.
What conditions does trial NCT05670782 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT05670782?
The interventions under investigation include: Placebo (DRUG), KM-819 (DRUG).
Who is sponsoring clinical trial NCT05670782?
This trial is sponsored by FAScinate Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05670782 being conducted?
This trial has 3 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05670782's enrollment target sits among peer trials
314 34th of 297 higher than 264 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI